Healthcare Realty Trust Analyst Ratings
Healthcare Realty Trust Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/12/2023 | 24.18% | JP Morgan | → $19 | Upgrades | Neutral → Overweight |
| 10/10/2023 | 11.11% | Scotiabank | $19 → $17 | Maintains | Sector Perform |
| 10/06/2023 | 11.11% | BMO Capital | $20 → $17 | Maintains | Market Perform |
| 10/03/2023 | 11.11% | Wedbush | → $17 | Initiates Coverage On | → Outperform |
| 08/22/2023 | 11.11% | Citigroup | $19 → $17 | Maintains | Neutral |
| 08/11/2023 | 56.86% | Barclays | $25 → $24 | Maintains | Equal-Weight |
| 05/11/2023 | 63.4% | Barclays | $24 → $25 | Maintains | Overweight |
| 04/19/2023 | — | Wells Fargo | Initiates Coverage On | → Equal-Weight | |
| 03/29/2023 | 56.86% | Barclays | $28 → $24 | Maintains | Overweight |
| 03/06/2023 | 30.72% | Credit Suisse | $23 → $20 | Downgrades | Outperform → Neutral |
| 12/14/2022 | 30.72% | Citigroup | $22.5 → $20 | Downgrades | Buy → Neutral |
| 12/02/2022 | 43.79% | JP Morgan | $28 → $22 | Maintains | Neutral |
| 09/19/2022 | 83.01% | Citigroup | $27 → $28 | Upgrades | Neutral → Buy |
| 08/11/2022 | 96.08% | SMBC Nikko | → $30 | Upgrades | Neutral → Outperform |
| 07/18/2022 | 89.54% | Credit Suisse | $34 → $29 | Maintains | Outperform |
| 05/10/2022 | 109.15% | Berenberg | $35 → $32 | Downgrades | Buy → Hold |
| 04/26/2022 | 115.69% | Barclays | → $33 | Initiates Coverage On | → Overweight |
| 02/01/2022 | — | Credit Suisse | Initiates Coverage On | → Outperform | |
| 01/07/2022 | 122.22% | BMO Capital | → $34 | Downgrades | Outperform → Market Perform |
| 08/20/2021 | — | Raymond James | Downgrades | Strong Buy → Market Perform | |
| 07/29/2021 | 115.69% | Morgan Stanley | $31 → $33 | Maintains | Equal-Weight |
| 03/31/2021 | 102.61% | Wells Fargo | $29 → $31 | Maintains | Equal-Weight |
| 03/15/2021 | 102.61% | Morgan Stanley | $30 → $31 | Maintains | Equal-Weight |
| 01/28/2021 | 109.15% | Scotiabank | → $32 | Initiates Coverage On | → Sector Perform |
| 01/13/2021 | 115.69% | Jefferies | $30 → $33 | Upgrades | Hold → Buy |
| 09/18/2020 | 115.69% | Capital One | → $33 | Upgrades | Equal-Weight → Overweight |
| 09/02/2020 | 109.15% | Stifel | → $32 | Reinstates | → Buy |
| 08/31/2020 | 128.76% | Raymond James | $34 → $35 | Upgrades | Outperform → Strong Buy |
| 04/29/2020 | 122.22% | Raymond James | $38 → $34 | Maintains | Outperform |
| 04/07/2020 | 89.54% | Citigroup | $38 → $29 | Downgrades | Buy → Neutral |
| 04/03/2020 | 69.93% | Wells Fargo | $33 → $26 | Maintains | Equal-Weight |
| 04/03/2020 | 96.08% | JP Morgan | $35 → $30 | Maintains | Neutral |
| 03/26/2020 | 63.4% | Morgan Stanley | $33 → $25 | Maintains | Equal-Weight |
| 03/12/2020 | 148.37% | Raymond James | $36 → $38 | Maintains | Outperform |
| 03/09/2020 | 181.05% | BMO Capital | $35 → $43 | Upgrades | Market Perform → Outperform |
| 12/20/2019 | 122.22% | Mizuho | → $34 | Assumes | → Neutral |
| 12/12/2019 | — | Citigroup | Upgrades | Neutral → Buy | |
| 11/26/2019 | 128.76% | Stifel | $33 → $35 | Upgrades | Hold → Buy |
| 09/17/2019 | 115.69% | Morgan Stanley | $31 → $33 | Maintains | Equal-Weight |
| 06/20/2019 | 122.22% | Citigroup | → $34 | Initiates Coverage On | → Neutral |
| 01/08/2019 | — | Raymond James | Upgrades | Underperform → Market Perform | |
| 11/13/2018 | 109.15% | Mizuho | → $32 | Upgrades | Neutral → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 2023年10月12日 | 24.18% | 摩根大通 | →$19 | 升级 | 中性→超重 |
| 2023年10月10日 | 11.11% | 加拿大丰业银行 | $19→$17 | 维护 | 行业表现 |
| 10/06/2023 | 11.11% | 蒙特利尔银行资本 | $20→$17 | 维护 | 市场表现 |
| 10/03/2023 | 11.11% | 韦德布什 | →$17 | 开始承保 | →跑赢大盘 |
| 2023年08月22日 | 11.11% | 花旗集团 | $19→$17 | 维护 | 中性 |
| 2023年08月11日 | 56.86% | 巴克莱 | $25→$24 | 维护 | 等重 |
| 2023年05月11日 | 63.4% | 巴克莱 | $24→$25 | 维护 | 超重 |
| 04/19/2023 | - | 富国银行 | 开始承保 | →等重 | |
| 03/29/2023 | 56.86% | 巴克莱 | $28→$24 | 维护 | 超重 |
| 03/06/2023 | 30.72% | 瑞士信贷 | $23→$20 | 评级下调 | 跑赢→中性 |
| 2022年12月14日 | 30.72% | 花旗集团 | $22.5→$20 | 评级下调 | 购买→中性 |
| 12/02/2022 | 43.79% | 摩根大通 | $28→$22 | 维护 | 中性 |
| 2022/09/19 | 83.01% | 花旗集团 | $27→$28 | 升级 | 中性→购买 |
| 2022年08月11日 | 96.08% | SMBC日兴 | →$30 | 升级 | 中性→表现优异 |
| 07/18/2022 | 89.54% | 瑞士信贷 | $34→$29 | 维护 | 跑赢大盘 |
| 2022年05月10日 | 109.15% | 贝伦伯格 | $35→$32 | 评级下调 | 购买→Hold |
| 04/26/2022 | 115.69% | 巴克莱 | →$33 | 开始承保 | →超重 |
| 02/01/2022 | - | 瑞士信贷 | 开始承保 | →跑赢大盘 | |
| 01/07/2022 | 122.22% | 蒙特利尔银行资本 | →$34 | 评级下调 | 跑赢→市场表现 |
| 08/20/2021 | - | 雷蒙德·詹姆斯 | 评级下调 | 强劲的购买→市场表现 | |
| 07/29/2021 | 115.69% | 摩根士丹利 | $31→$33 | 维护 | 等重 |
| 03/31/2021 | 102.61% | 富国银行 | $29→$31 | 维护 | 等重 |
| 03/15/2021 | 102.61% | 摩根士丹利 | $30→$31 | 维护 | 等重 |
| 2021年1月28日 | 109.15% | 加拿大丰业银行 | →$32 | 开始承保 | →行业表现 |
| 2021/01/13 | 115.69% | 杰富瑞 | $30→$33 | 升级 | 持有→购买 |
| 09/18/2020 | 115.69% | 大写一 | →$33 | 升级 | 等重→超重 |
| 09/02/2020 | 109.15% | Stifel | →$32 | 恢复 | →购买 |
| 08/31/2020 | 128.76% | 雷蒙德·詹姆斯 | $34→$35 | 升级 | 跑赢→强势买入 |
| 04/29/2020 | 122.22% | 雷蒙德·詹姆斯 | $38→$34 | 维护 | 跑赢大盘 |
| 04/07/2020 | 89.54% | 花旗集团 | $38→$29 | 评级下调 | 购买→中性 |
| 04/03/2020 | 69.93% | 富国银行 | $33→$26 | 维护 | 等重 |
| 04/03/2020 | 96.08% | 摩根大通 | $35→$30 | 维护 | 中性 |
| 03/26/2020 | 63.4% | 摩根士丹利 | $33→$25 | 维护 | 等重 |
| 03/12/2020 | 148.37% | 雷蒙德·詹姆斯 | $36→$38 | 维护 | 跑赢大盘 |
| 03/09/2020 | 181.05% | 蒙特利尔银行资本 | $35→$43 | 升级 | 市场表现优于→ |
| 2019年12月20日 | 122.22% | 瑞穗 | →$34 | 假设 | →中性 |
| 2019年12月12日 | - | 花旗集团 | 升级 | 中性→购买 | |
| 2019年11月26日 | 128.76% | Stifel | $33→$35 | 升级 | 持有→购买 |
| 2019/09/17 | 115.69% | 摩根士丹利 | $31→$33 | 维护 | 等重 |
| 2019年06月20日 | 122.22% | 花旗集团 | →$34 | 开始承保 | →中性 |
| 2019年08月01日 | - | 雷蒙德·詹姆斯 | 升级 | 表现逊于→市场表现 | |
| 2018年11月13日 | 109.15% | 瑞穗 | →$32 | 升级 | 中性→购买 |
What is the target price for Healthcare Realty Trust (HR)?
医疗房地产信托基金(HR)的目标价格是多少？
The latest price target for Healthcare Realty Trust (NYSE: HR) was reported by JP Morgan on October 12, 2023. The analyst firm set a price target for $19.00 expecting HR to rise to within 12 months (a possible 24.18% upside). 12 analyst firms have reported ratings in the last year.
JP摩根于2023年10月12日报道了Healthcare Realty Trust(纽约证券交易所代码：HR)的最新目标价。这家分析公司将目标价定为19.00美元，预计人力资源将在12个月内升至(可能上涨24.18%)。去年有12家分析公司公布了评级。
What is the most recent analyst rating for Healthcare Realty Trust (HR)?
Healthcare Realty Trust(HR)的最新分析师评级是多少？
The latest analyst rating for Healthcare Realty Trust (NYSE: HR) was provided by JP Morgan, and Healthcare Realty Trust upgraded their overweight rating.
对Healthcare Realty Trust(纽约证券交易所代码：HR)的最新分析师评级由摩根大通提供，Healthcare Realty Trust上调了其增持评级。
When is the next analyst rating going to be posted or updated for Healthcare Realty Trust (HR)?
Healthcare Realty Trust(HR)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Healthcare Realty Trust, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Healthcare Realty Trust was filed on October 12, 2023 so you should expect the next rating to be made available sometime around October 12, 2024.
分析师在进行了广泛的研究后得出股票评级，其中包括查阅公共财务报表，与Healthcare Realty Trust的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。医疗房地产信托基金的上一次评级是在2023年10月12日提交的，所以你应该预计下一次评级将在2024年10月12日左右的某个时候公布。
Is the Analyst Rating Healthcare Realty Trust (HR) correct?
分析师对Healthcare Realty Trust(HR)的评级正确吗？
While ratings are subjective and will change, the latest Healthcare Realty Trust (HR) rating was a upgraded with a price target of $0.00 to $19.00. The current price Healthcare Realty Trust (HR) is trading at is $15.30, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的医疗房地产信托(HR)评级被上调，目标价为0.00美元至19.00美元。Healthcare Realty Trust(HR)目前的交易价格为15.30美元，在分析师的预测范围内。